• 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
  • 2
    Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007; 369: 1703-1710.
  • 3
    Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005; 14: 98-107.
  • 4
    Collaborative Group on Epidemiological Studies of Ovarian Cancer; Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008; 371: 303-314.
  • 5
    Olsen CM, Green AC, Whiteman DC, et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007; 43: 690-709.
  • 6
    Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2002; 11: 822-828.
  • 7
    Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002; 11: 1531-1543.
  • 8
    Modugno F, Kip KE, Cochrane B, et al. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer. 2006; 118: 1292-1301.
  • 9
    Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117-1130.
  • 10
    Schatzkin A, Subar AF, Thompson FE, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol. 2001; 154: 1119-1125.
  • 11
    North American Association of Central Cancer Registries (NAACCR). Standards for completeness, quality, analysis, and management of data. Springfield, Ill: North American Association of Central Disease Registries; 2004.
  • 12
    Michaud DS, Midthune D, Hermansen S, et al. Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Registry Manage. 2005; 32: 70-75.
  • 13
    Fritz AG, Percy C, Jack A, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.
  • 14
    World Health Organization. Physical Status: The Use and Interpretation of Anthropometry. Report No. 854. Geneva: World Health Organization; 1995.
  • 15
    Cox DR. Regression models and life tables. J R Stat Soc (B). 1972; 34: 187-220.
  • 16
    Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. Breast. 2004; 13: 85-92.
  • 17
    Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 2001; 61: 6768-6776.
  • 18
    Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998; 90: 1774-1786.
  • 19
    Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2006; 207: 12-22.
  • 20
    Pralong FP, Gaillard RC. Neuroendocrine effects of leptin. Pituitary. 2001; 4: 25-32.
  • 21
    Schouten LJ, Rivera C, Hunter DJ, et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev. 2008; 17: 902-912.
  • 22
    Peterson NB, Trentham-Dietz A, Newcomb PA, et al. Relation of anthropometric measurements to ovarian cancer risk in a population-based case-control study (United States). Cancer Causes Control. 2006; 17: 459-467.
  • 23
    Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst. 2003; 95: 1244-1248.
  • 24
    Willett WC. Nutritional Epidemiology. 2nd ed. New York: Oxford University Press; 2006.
  • 25
    Spencer EA, Appleby PN, Davey GK, Key TJ. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr. 2002; 5: 561-565.
  • 26
    Beehler GP, Sekhon M, Baker JA, et al. Risk of ovarian cancer associated with BMI varies by menopausal status. J Nutr. 2006; 136: 2881-2886.
  • 27
    Brinton LA, Sakoda LC, Frederiksen K, et al. Relationships of uterine and ovarian tumors to pre-existing chronic conditions. Gynecol Oncol. 2007; 107: 487-494.
  • 28
    Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol. 2005; 96: 520-530.
  • 29
    Soegaard M, Jensen A, Hogdall E, et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1160-1166.